Recurrent pseudocellulitis due to gemcitabine: underrecognized and underreported?
Pseudocellulitis has been previously described with the use of chemotherapy agent gemcitabine. This condition is thought to occur due to vascular toxicity and increased localized permeability of the skin capillaries. We report herein a case of recurrent pseudocellulitis due to gemcitabine in a patient with metastatic pancreatic cancer. We believe this condition is underreported and underrecognized. Furthermore, it may be misdiagnosed as cellulitis and inappropriately treated with systemic antibiotics. As the diagnosis is clinical and the condition is self-limited, referral to other specialists is usually not required. Awareness of gemcitabine-induced pseudocellulitis is important in order to reassure the patients, their families, and non-oncology providers and to avoid unnecessary (and often costly) diagnostic work-up.
Department of Hematology-Oncology, St. Francis Hospital and Medical Center, Hartford, CT, USA c_dasanu@yahoo.com.
Constantin A
CA
Dasanu
Department of Internal Medicine, University of Connecticut Health Center, Farmington, CT, USA.
Bruno
B
Bockorny
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D002481:Cellulitis / Q000139:chemically induced* / Q000175:diagnosis; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000473:pathology; D012008:Recurrence; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine
Pseudocellulitis; chemotherapy; gemcitabine; skin toxicity